Cargando…

Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies

BACKGROUND: Risankizumab is a humanized IgG monoclonal antibody that selectively inhibits interleukin‐23 through binding the p19 subunit. In Phase 3 trials, risankizumab demonstrated superior efficacy compared with adalimumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Strober, B., Menter, A., Leonardi, C., Gordon, K., Lambert, J., Puig, L., Photowala, H., Longcore, M., Zhan, T., Foley, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818271/
https://www.ncbi.nlm.nih.gov/pubmed/32320088
http://dx.doi.org/10.1111/jdv.16521
_version_ 1783638801190486016
author Strober, B.
Menter, A.
Leonardi, C.
Gordon, K.
Lambert, J.
Puig, L.
Photowala, H.
Longcore, M.
Zhan, T.
Foley, P.
author_facet Strober, B.
Menter, A.
Leonardi, C.
Gordon, K.
Lambert, J.
Puig, L.
Photowala, H.
Longcore, M.
Zhan, T.
Foley, P.
author_sort Strober, B.
collection PubMed
description BACKGROUND: Risankizumab is a humanized IgG monoclonal antibody that selectively inhibits interleukin‐23 through binding the p19 subunit. In Phase 3 trials, risankizumab demonstrated superior efficacy compared with adalimumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis. Here, we evaluated the impact of baseline characteristics on efficacy of risankizumab compared with ustekinumab in patients with moderate‐to‐severe plaque psoriasis. METHODS: This analysis included all patients initially randomized to risankizumab or ustekinumab from the replicate, double‐blinded, randomized, placebo‐controlled phase 3 trials, UltIMMa‐1 (NCT02684370) and UltIMMa‐2 (NCT02684357). Patients received either risankizumab (150 mg) or ustekinumab (weight‐based; 45 or 90 mg per label) at weeks 0, 4, 16, 28 and 40. Efficacy was assessed as the proportion of patients achieving ≥90% improvement in Psoriasis Area and Severity Index (PASI 90) at weeks 16 and 52 by baseline patient demographics, disease characteristics and prior biologic exposure. Mean per cent improvement in PASI was calculated by body weight and body mass index at week 52. Missing efficacy data were imputed as non‐responders for categorical variables and last observation carried forward for continuous variables. Logistic regression analyses assessed for interactions between treatment and five independent variables (age, sex, weight, baseline PASI score and presence of psoriatic arthritis) at both weeks 16 and 52. RESULTS: Baseline patient demographics, disease characteristics and prior biologic exposure were similar between patients randomized to risankizumab (n = 598) and ustekinumab (n = 199). At weeks 16 and 52, risankizumab demonstrated superior efficacy compared with ustekinumab across these patient characteristics (P < 0.01). Logistic regression analyses demonstrated that risankizumab was superior to ustekinumab at weeks 16 and 52 in all models tested (P < 0.0001 for all). CONCLUSIONS: Risankizumab demonstrated consistent and superior efficacy compared with ustekinumab regardless of patient demographics, disease characteristics or prior biologic exposure.
format Online
Article
Text
id pubmed-7818271
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78182712021-01-29 Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies Strober, B. Menter, A. Leonardi, C. Gordon, K. Lambert, J. Puig, L. Photowala, H. Longcore, M. Zhan, T. Foley, P. J Eur Acad Dermatol Venereol Psoriasis BACKGROUND: Risankizumab is a humanized IgG monoclonal antibody that selectively inhibits interleukin‐23 through binding the p19 subunit. In Phase 3 trials, risankizumab demonstrated superior efficacy compared with adalimumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis. Here, we evaluated the impact of baseline characteristics on efficacy of risankizumab compared with ustekinumab in patients with moderate‐to‐severe plaque psoriasis. METHODS: This analysis included all patients initially randomized to risankizumab or ustekinumab from the replicate, double‐blinded, randomized, placebo‐controlled phase 3 trials, UltIMMa‐1 (NCT02684370) and UltIMMa‐2 (NCT02684357). Patients received either risankizumab (150 mg) or ustekinumab (weight‐based; 45 or 90 mg per label) at weeks 0, 4, 16, 28 and 40. Efficacy was assessed as the proportion of patients achieving ≥90% improvement in Psoriasis Area and Severity Index (PASI 90) at weeks 16 and 52 by baseline patient demographics, disease characteristics and prior biologic exposure. Mean per cent improvement in PASI was calculated by body weight and body mass index at week 52. Missing efficacy data were imputed as non‐responders for categorical variables and last observation carried forward for continuous variables. Logistic regression analyses assessed for interactions between treatment and five independent variables (age, sex, weight, baseline PASI score and presence of psoriatic arthritis) at both weeks 16 and 52. RESULTS: Baseline patient demographics, disease characteristics and prior biologic exposure were similar between patients randomized to risankizumab (n = 598) and ustekinumab (n = 199). At weeks 16 and 52, risankizumab demonstrated superior efficacy compared with ustekinumab across these patient characteristics (P < 0.01). Logistic regression analyses demonstrated that risankizumab was superior to ustekinumab at weeks 16 and 52 in all models tested (P < 0.0001 for all). CONCLUSIONS: Risankizumab demonstrated consistent and superior efficacy compared with ustekinumab regardless of patient demographics, disease characteristics or prior biologic exposure. John Wiley and Sons Inc. 2020-07-03 2020-12 /pmc/articles/PMC7818271/ /pubmed/32320088 http://dx.doi.org/10.1111/jdv.16521 Text en © 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Psoriasis
Strober, B.
Menter, A.
Leonardi, C.
Gordon, K.
Lambert, J.
Puig, L.
Photowala, H.
Longcore, M.
Zhan, T.
Foley, P.
Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
title Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
title_full Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
title_fullStr Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
title_full_unstemmed Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
title_short Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
title_sort efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase iii ultimma‐1 and ultimma‐2 studies
topic Psoriasis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818271/
https://www.ncbi.nlm.nih.gov/pubmed/32320088
http://dx.doi.org/10.1111/jdv.16521
work_keys_str_mv AT stroberb efficacyofrisankizumabinpatientswithmoderatetosevereplaquepsoriasisbybaselinedemographicsdiseasecharacteristicsandpriorbiologictherapyanintegratedanalysisofthephaseiiiultimma1andultimma2studies
AT mentera efficacyofrisankizumabinpatientswithmoderatetosevereplaquepsoriasisbybaselinedemographicsdiseasecharacteristicsandpriorbiologictherapyanintegratedanalysisofthephaseiiiultimma1andultimma2studies
AT leonardic efficacyofrisankizumabinpatientswithmoderatetosevereplaquepsoriasisbybaselinedemographicsdiseasecharacteristicsandpriorbiologictherapyanintegratedanalysisofthephaseiiiultimma1andultimma2studies
AT gordonk efficacyofrisankizumabinpatientswithmoderatetosevereplaquepsoriasisbybaselinedemographicsdiseasecharacteristicsandpriorbiologictherapyanintegratedanalysisofthephaseiiiultimma1andultimma2studies
AT lambertj efficacyofrisankizumabinpatientswithmoderatetosevereplaquepsoriasisbybaselinedemographicsdiseasecharacteristicsandpriorbiologictherapyanintegratedanalysisofthephaseiiiultimma1andultimma2studies
AT puigl efficacyofrisankizumabinpatientswithmoderatetosevereplaquepsoriasisbybaselinedemographicsdiseasecharacteristicsandpriorbiologictherapyanintegratedanalysisofthephaseiiiultimma1andultimma2studies
AT photowalah efficacyofrisankizumabinpatientswithmoderatetosevereplaquepsoriasisbybaselinedemographicsdiseasecharacteristicsandpriorbiologictherapyanintegratedanalysisofthephaseiiiultimma1andultimma2studies
AT longcorem efficacyofrisankizumabinpatientswithmoderatetosevereplaquepsoriasisbybaselinedemographicsdiseasecharacteristicsandpriorbiologictherapyanintegratedanalysisofthephaseiiiultimma1andultimma2studies
AT zhant efficacyofrisankizumabinpatientswithmoderatetosevereplaquepsoriasisbybaselinedemographicsdiseasecharacteristicsandpriorbiologictherapyanintegratedanalysisofthephaseiiiultimma1andultimma2studies
AT foleyp efficacyofrisankizumabinpatientswithmoderatetosevereplaquepsoriasisbybaselinedemographicsdiseasecharacteristicsandpriorbiologictherapyanintegratedanalysisofthephaseiiiultimma1andultimma2studies